Intuitive(US:ISRG) Globenewswireยท2025-10-21 20:05Core Insights - Intuitive Surgical reported strong financial results for Q3 2025, with a revenue increase of 23% year-over-year, reaching $2.51 billion, driven by higher procedure volumes and system placements [4][8]. Financial Performance - Q3 2025 revenue was $2.51 billion, up from $2.04 billion in Q3 2024, reflecting a 23% increase [4]. - Instruments and accessories revenue rose by 20% to $1.52 billion, compared to $1.26 billion in Q3 2024, attributed to a 19% growth in da Vinci procedure volume and a 52% increase in Ion procedure volume [5]. - Systems revenue for Q3 2025 was $590 million, an increase from $445 million in Q3 2024, with 427 da Vinci surgical systems placed, including 240 da Vinci 5 systems [6]. - GAAP income from operations increased to $760 million in Q3 2025 from $577 million in Q3 2024, while non-GAAP income from operations rose to $976 million from $755 million [7]. - GAAP net income attributable to Intuitive was $704 million, or $1.95 per diluted share, compared to $565 million, or $1.56 per diluted share, in Q3 2024 [9][10]. Operational Highlights - Worldwide procedures grew approximately 20% compared to Q3 2024, with da Vinci procedures increasing by 19% and Ion procedures by 52% [8]. - The installed base of da Vinci surgical systems grew to 10,763, a 13% increase from 9,539 in the previous year [8]. - The company repurchased 4.0 million shares for $1.92 billion during Q3 2025 [10]. 2025 Financial Outlook - The company anticipates worldwide da Vinci procedure growth of approximately 17% to 17.5% in 2025, compared to 17% in 2024 [17]. - Non-GAAP gross profit margin is expected to be between 67% and 67.5% of revenue in 2025, down from 69.1% in 2024, reflecting the impact of tariffs [17]. - Non-GAAP operating expense growth is projected to be between 11% and 13% in 2025, compared to 10% in 2024 [17].